ArticleMultiple sclerosis and related disorders2025
Neurofilament light chain levels differentiate ischemic from inflammatory optic neuropathies.
Article in Multiple sclerosis and related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Infectious optic neuropathy: the interplay between pathogens and the host immune system-a review of diagnostic and therapeutic dilemmas.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSerum neurofilament light chain (sNfL) levels may be useful for differentiating non-arteritic anterior ischemic optic neuropathy (NAION) and optic neuritis (ON). The purpose of the study is to determine the discriminatory capacity of sNfL in NAION versus aquaporin-4 (AQP4)-IgG positive neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) ON, and to evaluate if sNfL levels at attack correlate with visual outcomes.
methodsWe evaluated sNfL levels (pg/mL) in patients with acute, isolated, unilateral or bilateral optic neuropathy with AQP4-IgG or MOG-IgG positive ON and NAION and serum samples of 24 unaffected controls.
resultsThirteen AQP4-IgG+NMOSD, 13 MOGAD, 15 NAION, and 24 unaffected controls were included. sNfL levels differed between all cohorts (AQP4-IgG+NMOSD: 10.1 [IQR] 8.9-24.4]), MOGAD: 16.0 [IQR 10.5-24.2]; NAION: 36.9 [IQR 20.5-69.5]; unaffected controls: 6.5 [IQR 5.5-9.6]; p < 0.001). There was a difference in sNfL levels between ON and NAION (median 11.6 [IQR 9.3-24.4] versus 36.9 [IQR 20.5-69.5], p < 0.001). Serum Nfl of 60 pg/mL (Youden's index = 0.49; AUC = 0.82) provided sensitivity of 33 % and 100 % specificity when discriminating NAION from ON. Serum NfL levels were correlated with final visual acuity after adjusting for optic neuropathy etiology (model R DISCUSSION: sNfL levels may aid in discriminating between NAION and acute ON associated with AQP4-IgG+NMOSD and MOGAD and may predict long-term visual outcomes. However, results should be interpreted with caution as further studies are required using standardized z-scores in place of raw sNfL levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.